Tacrolimus, Sirolimus and Ustekinumab vs. Tacrolimus and Sirolimus for the Prevention of Acute Graft-Versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation
Latest Information Update: 17 Jul 2018
At a glance
- Drugs Ustekinumab (Primary) ; Sirolimus; Tacrolimus
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 15 Jun 2018 Status changed from active, no longer recruiting to completed.
- 09 Jan 2018 Planned end date changed from 1 Jul 2018 to 1 Jan 2019.